Neil Osterweil, Freelance Journalist Profile

Articles

Neoadjuvant Osimertinib in EGFR-Mutated NSCLC: New Data, Same Questions?

2 days ago | oncologynewscentral.com | Neil Osterweil

For patients with resectable non-small cell lung cancer (NSCLC) who have EGFR mutations, treatment with osimertinib (Tagrisso) before surgery with or without chemotherapy was associated with statistically significant improvements in major pathologic responses. Findings from the NeoADAURA trial were presented in an oral abstract session at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting by Jamie E. Chaft, MD, from Memorial Sloan Kettering Cancer Center in New York City.
Neoadjuvant Nivolumab (Opdivo) Plus Chemotherapy Improves Overall Survival in Resectable NSCLC

3 days ago | oncologynewscentral.com | Neil Osterweil

Data from the CheckMate 816 trial, published in The New England Journal of Medicine (NEJM) in 2022, showed that adding the immune checkpoint inhibitor nivolumab to neoadjuvant chemotherapy resulted in improved pathologic complete responses (pCRs) and event-free survival (EFS) for patients with resectable non-small cell lung cancer (NSCLC).
New CheckMate 77T Data Confirm Perioperative Immunotherapy Benefit in NSCLC

5 days ago | oncologynewscentral.com | Neil Osterweil

An updated analysis from the CheckMate 77T trial comparing perioperative nivolumab (Opdivo) to placebo in patients with resectable non-small cell lung cancer (NSCLC) show that the event-free survival (EFS) benefit seen with the immune checkpoint inhibitor in earlier analyses continues with longer follow-up, now nearing 5 years.
Nuevo esquema diagnóstico de enfermedad pulmonar obstructiva crónica identifica a más personas en riesgo

5 days ago | espanol.medscape.com | Neil Osterweil

SAN FRANCISCO, USA. Nuevo esquema diagnóstico que incorpora tomografía axial computarizada torácica y síntomas respiratorios al diagnosticar enfermedad pulmonar obstructiva crónica puede ayudar a identificar mejor a pacientes con riesgo de malos resultados respiratorios y a descartar a aquellos con obstrucción del flujo aéreo que no presentan síntomas respiratorios ni signos de enfermedad pulmonar estructural.
PAXG Beats mFOLFIRINOX in Pancreatic Cancer for Event-Free Survival

5 days ago | oncologynewscentral.com | Neil Osterweil

For patients with resectable or borderline resectable pancreatic ductal adenocarcinoma (PDAC), neoadjuvant therapy with a combination of (P) cisplatin, (A) nab-paclitaxel, (X) capecitabine, and (G) gemcitabine (PAXG) improved event-free survival (EFS) compared with the modified FOLFIRINOX regimen (fluorouracil, irinotecan, and oxaliplatin), said investigators from the phase 3 CASSANDRA trial.
Phase 3 Breast Cancer Trial Shows PFS Benefit in ctDNA-Guided Treatment Ahead of Disease Progression

6 days ago | oncologynewscentral.com | Neil Osterweil

Patients with hormone receptor (HR)-positive, HER2-negative breast cancer who had evidence of emerging ESR1 mutations in circulating tumor DNA (ctDNA) during first-line therapy with an aromatase inhibitor (AI) and a CDK4/6 inhibitor had delayed disease progression and better quality of life when the AI was swapped out for the investigational next-generation oral selective estrogen receptor degrader camizestrant.
Nariz electrónica puede oler los subtipos de enfermedad pulmonar intersticial

6 days ago | espanol.medscape.com | Neil Osterweil

SAN FRANCISCO, USA. Los perros adiestrados para olfatear enfermedades pulmonares podrían tener que buscar otro trabajo si un sensor de "nariz electrónica" en fase de desarrollo llega a generalizarse en la práctica clínica.
Tumor-Treating Electrical Fields Improve Overall Survival in Pancreatic Cancer

6 days ago | oncologynewscentral.com | Neil Osterweil

Final results of the phase 3 PANOVA-3 study show that even small gains in overall survival are big news in pancreatic cancer. In the trial, patients with locally advanced pancreatic adenocarcinoma (LA-PAC) who underwent therapy with tumor-treating fields (TTFields) therapy added to gemcitabine and nab-paclitaxel had a modest but statistically significant improvement of 2 months in overall survival (OS) compared with gemcitabine/nab-paclitaxel alone.
Head-to-Head Trial

1 week ago | oncologynewscentral.com | Neil Osterweil

In a head-to-head trial of second-line therapies for patients with HER2-positive unresectable or metastatic gastric cancer or gastroesophageal junction adenocarcinoma (GC/GEJA), the antibody-drug conjugate trastuzumab deruxtecan (T-DXd; Enhertu) was associated with higher response rates and longer survival than the combination of ramucirumab (Cyramza) and paclitaxel.
Deupirfenidone Shows Promise Against IPF-Linked Lung Decline

1 week ago | medscape.com | Neil Osterweil

SAN FRANCISCO — A molecular variant of an older, hard-to-tolerate antifibrotic agent showed promise for reducing decline in forced vital capacity (FVC) over 26 weeks among patients with idiopathic pulmonary fibrosis (IPF). These findings come from the phase 2B ELEVATE IPF trial, results of which were reported at the American Thoracic Society (ATS) 2025 International Conference here.